Here are the details: An effective treatment, until it isn't: The UW–Madison team sought to understand why some patients with certain non-Hodgkin's lymphomas that originate in white blood cells ...

Non-Hodgkin lymphomas can be classified according to the speed at which they progress. Those that grow and spread slowly are described as ‘indolent’, one of the most common types of which is ...

The following is a summary of “Hematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre ...

Each year, about 100,000 patients worldwide are affected by T-cell leukemias and lymphomas. Adults with relapsed T-cell cancers have limited therapeutic options and five-year survival rates of 7 ...

Doctors group B-cell lymphomas based on: How the cancer cells look under a microscope Whether the cancer cells have certain proteins on their surface What kinds of gene changes are inside the ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape.